

Politics
Prognosis

PLAINTIFF'S EXHIBIT
q4

Frequent Boosters Spur Warning on Immune Response

Advertisement



Omicron to Be Gone by Fourth of July: Johns Hopkins

By Irina Anghel

January 11, 2022 at 12:10 PM EST *Corrected January 12, 2022 at 12:27 PM EST*

European Union regulators warned that frequent Covid-19 booster shots could adversely affect the immune response and may not be feasible.

Repeat booster doses every four months could eventually weaken the immune response and tire out people, according to the [European Medicines Agency](#). Instead, countries should leave more time between booster programs and tie them to the onset of the cold season in each hemisphere, following the blueprint set out by influenza vaccination strategies, the agency said.

The advice comes as some countries consider the possibility of offering people second booster shots in a bid to provide further protection against surging omicron infections. Earlier this month Israel became the first nation to start administering a second booster, or fourth shot, to those over 60. The U.K. has said that boosters are providing good levels of protection and there is no need for a second booster shot at the moment, but will review data as it evolves.

More from

Bloomberg Prognosis

GSK Drug Fails to Halt Blood Cancer Worsening in Advanced Study

China's Guangzhou Warns of Covid-Spread Risks as Cases Climb

China to 'Unswervingly' Keep to Covid Zero Policy, Dashing Hopes

Regeneron, Bayer Offer More Promising Data for Aging Eye Drug

Boosters “can be done once, or maybe twice, but it’s not something that we can think should be repeated constantly,” Marco Cavaleri, the EMA head of biological health threats and vaccines strategy, said at a press briefing on Tuesday. “We need to think about how we can transition from the current pandemic setting to a more endemic setting.”

The EU regulator also said at the briefing that oral and intravenous antivirals, such as Paxlovid and Remdesivir, maintain their efficacy against omicron. The agency said that April is the soonest it could approve a new vaccine targeting a specific variant, as the process takes about three to four months. Some of the world’s largest vaccine-makers have said they are looking at producing vaccines that could target new variants.

– *With assistance by April Roach*

(Changes headline and first two sentences to clarify EMA is referring to the immune response not immune system)

The latest in health, medicine and science — and what it means for you. The latest in health, medicine and science — and what it means for you. The latest in health, medicine and science — and what it means for you.

Get the latest from Bloomberg’s global team of health reporters with the Prognosis newsletter. Get the latest from Bloomberg’s global team of health reporters with the Prognosis newsletter. Get the latest from Bloomberg’s global team of health reporters with the Prognosis newsletter.

Enter your email

Please enter a valid email address

By submitting my information, I agree to the [Privacy Policy](#) and [Terms of Service](#) and to receive offers and promotions from Bloomberg.
